PUBLISHER: Allied Market Research | PRODUCT CODE: 1193076
PUBLISHER: Allied Market Research | PRODUCT CODE: 1193076
The global cardiac mapping market was valued at $2,625.0 million in 2021, and is projected to reach $4,572.17 million by 2031, registering a CAGR of 5.7% from 2022 to 2031.
Over the past ten years, interventional electrophysiology has advanced significantly. One of the most sophisticated methods used to collect and present the information obtained from an ECG is cardiac mapping. The technique involves identifying geographical and temporal distribution of cardiac electrical signals during a specific heartbeat. In recent years, innovative mapping methods have transformed the clinical electrophysiology laboratory and provided fresh insights to the mechanisms behind arrhythmias. In addition, there is a huge improvement in the resolution, three-dimensional spatial localization, and speed of acquisition of cardiac activity maps.
According to the Centers for Disease Control and Prevention, CDC, more than 454,000 hospitalizations with atrial fibrillation as the primary diagnosis happens each year in the U.S. This rise in incidence of cardiovascular diseases among all age groups owing to a sedentary lifestyle, rise in obesity, lack of physical fitness and stress, is expected to lead to sales of cardiac mapping systems on a large scale.
Furthermore, the growth of the cardiac mapping market is anticipated to be facilitated by the introduction of numerous cutting-edge diagnostic technologies by medical device companies, increase in the demand for accurate diagnosis of serious cardiac diseases, and availability of interventional cardiologists with the necessary training in developed economies.
The U.S. Department of Health & Human Services initiated a national campaign called 'Million Hearts', which aims to stop 1 million heart attacks and strokes in the next five years (from January 2022 to December 2026). It focuses on adopting a condensed list of priorities and goals that are supported by research and can enhance cardiovascular health for everyone. Thus, such more initiatives and funding provided by the government are expected to provide prevalence of factors causing the market growth.
In addition, rise in investment for research and development of the advanced and precise diagnostic tools by public and private players in the market with an aim to improve health care infrastructure and increase in adoption by the interventional cardiologists in hospitals are the key factors for the expansion of the cardiac mapping market. For instance, the development of the CardioInsight Noninvasive 3D Mapping System uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface and displays interactive 3-D color maps including activation, composite, and phase maps.
However, the market is expected to be significantly constrained in the near future by factors, such as lack of awareness about these systems in developing nations, expensive price, and minor risks involved in the cardiac mapping operation.
The cardiac mapping market is segmented on the basis of product, indication, end user, and region. By product, it is divided into contact cardiac mapping systems and non-contact cardiac mapping systems. Further, the contact cardiac mapping systems segment is divided into electroanatomical mapping, basket catheter mapping, and traditional endocardial catheter mapping. On the basis of indication, the market is segmented into atrial fibrillation, atrial flutter, AVNRT, and others. According to end user, the market is segmented into hospitals, clinics, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbott Laboratories, Acutus Medical Inc., APN Healthcare, BioSig Technologies, Boston Bioscientific Corporation, EPMap Systems, Johnson And Johnson (Biosense Webster), Kardium Inc., Koninklijke Philips, Lepu Medical Technology, Medtronic Plc., MicroPort Scientific Corporation, and others.
Key Benefits For Stakeholders
By End User
By Product
By Indication
By Region